- Home
- MAGH vs ALXO Comparison
MAGH vs ALXO Comparison
Compare MAGH & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAGH
- ALXO
- Stock Information
- Founded
- MAGH 2012
- ALXO 2015
- Country
- MAGH Singapore
- ALXO United States
- Employees
- MAGH N/A
- ALXO N/A
- Industry
- MAGH Engineering & Construction
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- MAGH Industrials
- ALXO Health Care
- Exchange
- MAGH Nasdaq
- ALXO Nasdaq
- Market Cap
- MAGH 51.8M
- ALXO 58.9M
- IPO Year
- MAGH 2025
- ALXO 2020
- Fundamental
- Price
- MAGH $1.11
- ALXO $1.10
- Analyst Decision
- MAGH
- ALXO Strong Buy
- Analyst Count
- MAGH 0
- ALXO 6
- Target Price
- MAGH N/A
- ALXO $3.30
- AVG Volume (30 Days)
- MAGH 648.0K
- ALXO 1.7M
- Earning Date
- MAGH 01-01-0001
- ALXO 11-06-2025
- Dividend Yield
- MAGH N/A
- ALXO N/A
- EPS Growth
- MAGH N/A
- ALXO N/A
- EPS
- MAGH 0.03
- ALXO N/A
- Revenue
- MAGH $13,529,576.00
- ALXO N/A
- Revenue This Year
- MAGH N/A
- ALXO N/A
- Revenue Next Year
- MAGH N/A
- ALXO N/A
- P/E Ratio
- MAGH $35.69
- ALXO N/A
- Revenue Growth
- MAGH 10.71
- ALXO N/A
- 52 Week Low
- MAGH $0.99
- ALXO $0.40
- 52 Week High
- MAGH $5.15
- ALXO $2.36
- Technical
- Relative Strength Index (RSI)
- MAGH N/A
- ALXO 59.62
- Support Level
- MAGH N/A
- ALXO $0.96
- Resistance Level
- MAGH N/A
- ALXO $1.26
- Average True Range (ATR)
- MAGH 0.00
- ALXO 0.14
- MACD
- MAGH 0.00
- ALXO -0.00
- Stochastic Oscillator
- MAGH 0.00
- ALXO 67.32
About MAGH Magnitude International Ltd Ordinary Shares
Magnitude International Ltd is providing electrical installation services to customers in both the private and public sectors in Singapore. It includes the planning, design, material selection, installation, testing, commissioning and certification of the electrical equipment/systems to be installed. The Group's revenue is derived from Singapore.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.